/
MLAB
$99.53-$2.89 (-2.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$565.9M
6M shares
52-week range
$55.45 – $113.99
75% from low
Sector
INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Exchange
NASDAQ
CS
Borrow rate
0.46%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-171.64
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.1M | $117.7M | $133.9M | $184.3M | $219.1M | $216.2M | $241.0M | $249.1M |
| Cost of revenue | $42.2M | $52.3M | $46.9M | $75.2M | $85.4M | $82.9M | $90.1M | $90.9M |
| Gross profit | $60.9M | $65.4M | $87.0M | $109.1M | $133.7M | $133.3M | $150.9M | $158.3M |
| Gross margin | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| R&D | $3.5M | $6.4M | $10.4M | $15.8M | $20.5M | $19.3M | $19.5M | $20.3M |
| Operating income | $9.8M | $7.9M | $12.4M | $4.7M | $3.3M | −$272.1M | $16.3M | $18.5M |
| EBITDA | $18.1M | $22.4M | $28.0M | $32.5M | $37.5M | −$238.4M | $42.3M | $35.3M |
| Net income | $7.5M | $1.8M | $3.3M | $1.9M | $930.0K | −$254.2M | −$2.0M | $6.7M |
| Net margin | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| EPS (diluted) | 1.86 | 0.31 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 | 1.21 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $259M | $11.78 | $11.70–$11.90 | 1 |
| 2028 | $272M | $12.36 | $12.28–$12.48 | 2 |
| 2029 | $281M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$21.29
Price
$99.53
Implied downside
-79%
Peer comparison
Mesa Laboratories Inc
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
www.mesalabs.com- Employees
- 717
- IPO / List date
- Feb 29, 1984
- HQ
- LAKEWOOD, CO
Held by traders on TradeandTell
No one on the platform currently holds MLAB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 31,600 | $2.8M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.64% ($0.64/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.1600 | 2026-06-15 |
| 2026-02-27 | $0.1600 | 2026-03-16 |
| 2025-11-28 | $0.1600 | 2025-12-15 |
| 2025-08-29 | $0.1600 | 2025-09-15 |
| 2025-05-30 | $0.1600 | 2025-06-16 |
| 2025-02-28 | $0.1600 | 2025-03-17 |
| 2024-11-29 | $0.1600 | 2024-12-16 |
| 2024-08-30 | $0.1600 | 2024-09-16 |
| 2024-05-31 | $0.1600 | 2024-06-14 |
| 2024-02-28 | $0.1600 | 2024-03-15 |
Recent trades on TradeandTell
No one on the platform has traded MLAB yet.
